Phase 1 Study of Rezatapopt, a p53 Reactivator, in <i>TP53</i> Y220C–Mutated Tumors
In this phase 1 study involving heavily pretreated patients, the most common adverse events associated with rezatapopt were nausea and vomiting. Antitumor activity occurred across multiple tumor types, providing proof of concept for p53 reactivation. (Funded by PMV Pharmaceuticals; PYNNACLE ClinicalTrials.gov number, NCT04585750.).
Authors
- Dale R. Shepard (ORCID: https://orcid.org/0000-0003-4310-6019)
- A. Vandross
- Leila Alland
- Aparna R. Parikh (ORCID: https://orcid.org/0000-0002-5245-7841)
- Melissa L. Johnson (ORCID: https://orcid.org/0000-0001-9874-1314)
- Anthony W. Tolcher (ORCID: https://orcid.org/0000-0002-6322-9721)
- John A. Thompson (ORCID: https://orcid.org/0000-0003-2991-5194)
- Shivaani Kummar
- Alison M. Schram (ORCID: https://orcid.org/0000-0002-6070-2413)
- Kim LeDuke
- Marc Fellous
- Deepika Jalota
- E. E. Dumbrava
- Lisa Sheehan
- Anthony B. El-Khoueiry
- Geoffrey I. Shapiro
- Arshad Haque
Institutions
- University of Southern California (US)
- Cleveland Clinic (US)
- Memorial Sloan Kettering Cancer Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- Oregon Health & Science University (US)
- Sarah Cannon Research Institute (GB)
- Princeton University (US)
- Texas Oncology (US)
- Massachusetts General Hospital (US)
- Fred Hutch Cancer Center (US)
- Sarah Cannon (US)
- USC Norris Comprehensive Cancer Center (US)
- Dana-Farber Cancer Institute (US)
- Hutchinson (United Kingdom) (GB)
- 21c Consultancy (United Kingdom) (GB)
Publication Details
- Journal
- New England Journal of Medicine
- Published
- 2026-02-25
- DOI
- https://doi.org/10.1056/nejmoa2508820
- Citations
- 1
- Primary Topic
- Cancer-related Molecular Pathways
- Type
- article
- Field-Weighted Citation Impact
- 24.20